Accepted Manuscript

Cases of *ALK*-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy

Deepa Rangachari, MD, Xiuning Le, MD, PhD, Meghan Shea, MD, Mark S. Huberman, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

PII: S1556-0864(17)30440-9

DOI: 10.1016/j.jtho.2017.06.002

Reference: JTHO 610


To appear in: Journal of Thoracic Oncology

Received Date: 23 May 2017

Accepted Date: 2 June 2017

Please cite this article as: Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB, Cases of *ALK*-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.06.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Cases of *ALK*-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy

Deepa Rangachari, MD¹; Xiuning Le, MD, PhD¹; Meghan Shea, MD¹; Mark S. Huberman, MD¹; Paul A. VanderLaan, MD, PhD²; Susumu S. Kobayashi, MD, PhD¹; Daniel B. Costa, MD, PhD^{1*}

¹ Department of Medicine, ² Department of Pathology, Beth Israel Deaconess Medical Center,

Harvard Medical School, Boston, MA

Correspondence to:

^{*}Daniel B. Costa, MD, PhD - Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Av., Boston, MA 02215 Phone: 617-667-9236 Fax: 617-975-5665 Emails: dbcosta@bidmc.harvard.edu

Running Title: 5-year PFS with crizotinib Word count: 500 Figures: 3 References: 5

Manuscript type: Case Report

Keywords: lung cancer; adenocarcinoma; ALK; survival; 5-year; crizotinib

Funding/Grant Support: This work was funded in part through an American Cancer Society grant RSG 11-186 (DBC), National Cancer Institute grants P50CA090578 (DBC), R01CA169259 (SSK) and R21CA17830 (SSK), and internal donations to Beth Israel Deaconess Medical Center.

Download English Version:

https://daneshyari.com/en/article/8787936

Download Persian Version:

https://daneshyari.com/article/8787936

Daneshyari.com